Clearmind Medicine (NASDAQ:CMND) Upgraded to Sell at Wall Street Zen

Clearmind Medicine (NASDAQ:CMND) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday.

Clearmind Medicine Stock Performance

CMND stock opened at $3.07 on Friday. The company has a market capitalization of $3.13 million, a P/E ratio of -0.02 and a beta of 0.64. The company has a fifty day moving average price of $5.36 and a 200-day moving average price of $14.74. Clearmind Medicine has a 52-week low of $2.10 and a 52-week high of $524.00.

Clearmind Medicine (NASDAQ:CMND) last posted its quarterly earnings data on Monday, June 15th. The company reported ($6.78) earnings per share for the quarter.

Insider Buying and Selling at Clearmind Medicine

In other news, major shareholder Financial Lp Hrt sold 22,139 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total transaction of $73,280.09. Following the completion of the transaction, the insider directly owned 81,353 shares in the company, valued at $269,278.43. This trade represents a 21.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 252,615 shares of company stock valued at $117,933 over the last ninety days.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.